Gland Pharma promoter Fosun divests 6% stake for Rs 1,754 cr via bulk deal

Chinese drug firm Fosun Pharma, through its arm Fosun Pharma Industrial Pte, offloaded the shares of Hyderabad-based Gland Pharma through a bulk deal on the BSE

Divestment, privatisation, stake sale, disinvestment
Shares of Gland Pharma fell 0.65 per cent to close at Rs 1,826.60 apiece on the BSE.
Press Trust of India New Delhi
2 min read Last Updated : Jun 19 2024 | 11:48 PM IST

Fosun Pharma, one of the promoters of Gland Pharma, on Wednesday divested a 6 per cent stake for Rs 1,754 crore through an open market transaction.

Chinese drug firm Fosun Pharma, through its arm Fosun Pharma Industrial Pte, offloaded the shares of Hyderabad-based Gland Pharma through a bulk deal on the BSE.

According to the bulk deal data available on the BSE, Fosun Pharma Industrial Pte disposed of 99 lakh shares or a 6 per cent stake in Gland Pharma.

The shares were sold at an average price of Rs 1,771.81 apiece, taking the deal size to Rs 1,754.09 crore.

After the stake sale, Fosun Pharma's shareholding in Gland Pharma has declined to 51.86 per cent from 57.86 per cent.
 

Meanwhile, UBS Principal Capital Asia picked up 8.25 lakh shares, amounting to a 0.5 per cent stake in Gland Pharma.

The shares were purchased at an average price of Rs 1,771.05 per piece, taking the transaction value to Rs 146.11 crore.

Details of the other buyers of Gland Pharma's shares could not be ascertained.

Shares of Gland Pharma fell 0.65 per cent to close at Rs 1,826.60 apiece on the BSE.

In October 2017, Fosun Pharma acquired approximately 74 per cent of Gland Pharma at a valuation of not more than $1.09 billion.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Gland PharmaFosunFosun Pharmaceutical

First Published: Jun 19 2024 | 11:45 PM IST

Next Story